Amgen (AMGN), Allergan (AGN) Announce ABP 215 Phase 3 Met Primary, Secondary Endpoints
Tweet Send to a Friend
Amgen (NASDAQ: AMGN)and Allergan plc. (NYSE: AGN) announced a Phase 3 study of biosimilar candidate ABP 215 met its primary ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
